Multiplex Assay Kit for Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay)

P3NP; N-Propeptide Of Type III Procollagen; Procollagen III Amino Terminal Propeptide

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 83-97 88
EDTA plasma(n=5) 96-104 101
heparin plasma(n=5) 89-103 97
sodium citrate plasma(n=5) 78-101 82

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 98-105% 80-90% 84-91% 89-101%
EDTA plasma(n=5) 98-105% 80-94% 78-101% 92-101%
heparin plasma(n=5) 88-102% 96-105% 80-93% 96-103%
sodium citrate plasma(n=5) 94-101% 96-104% 78-99% 78-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:PIIINP) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Molecular Biology Reports Characterization of the specific and sustained GH1 expression induced by rAAV2/1 in normal adult male rats PubMed: 20204528
Obesity Surgery A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis PubMed: 20532833
Liver Biopsy Comparison of Five Liver Fibrosis Indexes with Serum Levels of Laminin and N Terminal Peptide of Procollagen Type III in Chronic Hepatitis Patients Intechopen: 18785
Trials Is there benefit in optimising heart failure treatment in over-80 year-old patients? (HF-80 study): study protocol for a randomized controlled trial. Trials: 1745-6215
American Journal of Hypertension Aliskiren and Perindopril Reduce the Levels of Transforming Growth Factor-β in Patients With Non-Diabetic Kidney Disease Nature: 201214
Arthritis Research and Therapy Raised circulating tenascin-C in rheumatoid arthritis. PubMed: 23193984
American Heart Journal Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure. PubMed: 23067911
hepatology research Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. PubMed: 22734888
Digestive and Liver Disease Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial Pubmed: 23238034
Journal of Infectious Diseases Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis Pubmed: 23922364
International Urogynecology Journal Prevalence, etiology and risk factors of pelvic organ prolapse in premenopausal primiparous women Springer: Source
Journal of Clinical and Experimental Hepatology Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis ScienceDirect: S0973688314000073
Der Urologe Retroperitoneale Fibrose Springer:Source
Ultrasound in Obstetrics &amp; Gynecology The status of the pelvic floor in young primiparous women Wiley:Source
PLoS One. Clinical significance of markers of collagen metabolism in rheumatic mitral valve disease Pubmed:24603967
Clin Chim Acta. Serum and urinary procollagen III aminoterminal propeptide as a biomarker of obstructive nephropathy in children Pubmed:24768785
BMC Gastroenterol. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis-a novel animal model Pubmed:24884574
Toxicology. DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2 Pubmed:24945829
Southeast Asian J Trop Med Public Health. Correlation of HBsAg titers with serum fibrotic maker in patients with chronic hepatitis B infection. Pubmed:24974647
The American Journal of Cardiology Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease Pubmed:25073565
Ann Rheum Dis. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease Pubmed:25143523
Scientific Reports Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension PubMed: 25747153
Int J Mol Sci The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension PubMed: 25984599
Viral Hepatitis Journal The Relationship of the Degree of Hepatic Fibrosis with Hyaluronic Acid, Type 4 Collagen, and Procollagen Type 3 N-Terminal Peptide Levels in Patients with Chronic Viral Hepatitis Openview: 8A0B8C97D72C61741371F33508760B75
International Journal of Experimental Pathology Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet doi:10.1111
Heart Rhythm.  Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population Pubmed:26776557
BMJ Open Sport Exerc Med Procollagen markers in microdialysate can predict patient outcome after Achilles tendon rupture content:2
Inflammation Research Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy pubmed:27516211
Heart & Vessels Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR pubmed:28004175
american journal of physiology-renal physiology Extracellular microRNA signature in chronic kidney disease. pubmed:28077372
Cellular Physiology and Biochemistry Renal Denervation Attenuates Multi-Organ Fibrosis and Improves Vascular Remodeling in Rats with Transverse Aortic Constriction Induced Cardiomyopathy pubmed:27889753
PLoS One. Procollagen C-Proteinase Enhancer 1 (PCPE-1) as a Plasma Marker of Muscleand Liver Fibrosis in Mice. pubmed:27458976
International Journal of Cardiology 5-methoxytryptophan is a potential marker for post-myocardial infarction heart failure - apreliminary approach to clinical utility. pubmed:27526355
Transplant Proc Urinary Type III Procollagen Is Associated With Chronic Allograft Dysfunction and Predicts Graft Survival. pubmed:28219585
Knee Surg Sports Traumatol Arthrosc Achilles tendon rupture healing is enhanced by intermittent pneumatic compression upregulating collagen type I synthesis pubmed:28668970
Antiviral Therapy Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Study pubmed:28054933
Molecular Medicine Reports Profilin‑1 contributes to cardiac injury induced by advanced glycation end‑products in rats pubmed:28901418
Biomarkers Medicial Relationship of biomarkers of extracellular matrix with myocardial function in Type 2 diabetes mellitus pubmed:28685602
Heart and Vessels Left ventricular reverse remodeling is not related to biopsy‑detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR 10.1007/s00380-016-0930-y
Clinical Infectious Diseases Matrix Degradation in Human Immunodeficiency Virus Type 1–Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study 10.1093/cid/cix231
Cytokine 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis. pubmed:28460256
Advanced Healthcare Materials Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. pubmed:29120858
American Journal of Kidney Diseases Urinary Biomarkers of Kidney Tubular Damage and Risk of Cardiovascular Disease and Mortality in Elders Pubmed:29602632
Angiology The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Study article:10.1007
Hernia Circulating matrix metalloproteinases and procollagen propeptides in inguinal hernia Pubmed:29484522
Cardiovascular Journal of Africa Assessment of myocardial fibrosis by late gadolinium enhancement imaging and biomarkers of collagen metabolism in chronic rheumatic mitral regurgitation. Pubmed:29443354
Turk Kardiyol Dern Ars.  Association between reverse electrical remodeling and cardiac fibrosis markers in patients with cardiac resynchronization therapy Pubmed:29512624
Кардиоваскулярная терапия и профилактика N-терминальный пропептид проколлагена III типа в качестве возможного сывороточного маркера фиброза миокарда у больных сахарным диабетом 2 … :
Clinical Infectious Diseases Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation through Mutation or Therapeutic Blockade Pubmed: 30239650
Anatolian Journal of Cardiology microRNA-29a inhibits cardiac fibrosis in Sprague-Dawley rats by downregulating the expression of DNMT3A. Pubmed: 30297596
Contemporary Clinical Trials Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design Doi: 10.1016/j.cct.2018.10.012
Arthritis Research & Therapy Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related disease Pubmed: 30547825
American Journal of Respiratory and Critical Care Medicine Identification and Modulation of Microenvironment is Crucial for Effective MSC Therapy in Acute Lung Injury Pubmed: 30521764
Direktor: Prof. Dr. med. Andreas Mügge
Scientific Reports Low fibrosis biomarker levels predict cardiac resynchronization therapy response Pubmed: 30988339
American Journal of Translational Research Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotype Pubmed: 30972180
Food and Chemical Toxicology Gum Acacia mitigates diclofenac nephrotoxicity by targeting monocyte chemoattractant protein-1, complement receptor-1 and pro-apoptotic pathways Pubmed: 31042592
Digestive diseases and sciences Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index Pubmed: 31468264
Journal of Diabetes Research Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis Pubmed: 33224989
BMC GASTROENTEROLOGY Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy Pubmed: 33069226
european heart journal A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial Pubmed: 32578850
Ассоциации толщины эпикардиального жира и циркулирующих маркеров фиброза миокарда у пациентов с инфарктом миокарда
J Am Geriatr Soc Association of Non©\Steroidal Anti©\Inflammatory Drugs with Kidney Health in Ambulatory Older Adults 33305369
Aging (Albany NY) Prognostic potential of cardiac structural and functional parameters and N-terminal propeptide of type III procollagen in predicting cardiac fibrosis one year after?¡­ 33431713
PeerJ Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial 33614272
Open Forum Infectious Diseases Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis 34104667
European Heart Journal A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes 32578850
Nutrients The Effect of Daily Methylsulfonylmethane (MSM) Consumption on High-Density Lipoprotein Cholesterol in Healthy Overweight and Obese Adults: A Randomized … 34684621
J Diabetes Res Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus 34778465
Scandinavian Cardiovascular Journal Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy 34296634
J. Clin. Med Simple Predictors for Cardiac Fibrosis in Patients with Type 2 Diabetes Mellitus: The Role of Circulating Biomarkers and Pulse Wave Velocity Pubmed:35628969
Biomolecules Increase in Serum MMP-9 and TIMP-1 Concentrations during Alcohol Intoxication in Adolescents—A Preliminary Study Pubmed:35625637
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPA573Ra01 Recombinant Procollagen III N-Terminal Propeptide (PIIINP) Positive Control; Immunogen; SDS-PAGE; WB.
CPA573Ra21 OVA Conjugated Procollagen III N-Terminal Propeptide (PIIINP) Immunogen; SDS-PAGE; WB.
CPA573Ra31 KLH Conjugated Procollagen III N-Terminal Propeptide (PIIINP) Immunogen; SDS-PAGE; WB.
PAA573Ra01 Polyclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
PAA573Ra08 Polyclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
MAA573Ra25 Monoclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
MAA573Ra27 Monoclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
MAA573Ra24 Monoclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
MAA573Ra23 Monoclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
MAA573Ra21 Monoclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
MAA573Ra22 Monoclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
MAA573Ra29 Monoclonal Antibody to Procollagen III N-Terminal Propeptide (PIIINP) WB; IHC; ICC; IP.
SEA573Ra ELISA Kit for Procollagen III N-Terminal Propeptide (PIIINP) Enzyme-linked immunosorbent assay for Antigen Detection.
CEA573Ra ELISA Kit for Procollagen III N-Terminal Propeptide (PIIINP) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA573Ra CLIA Kit for Procollagen III N-Terminal Propeptide (PIIINP) Chemiluminescent immunoassay for Antigen Detection.
LMA573Ra Multiplex Assay Kit for Procollagen III N-Terminal Propeptide (PIIINP) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.
KSA573Ra01 ELISA Kit DIY Materials for Procollagen III N-Terminal Propeptide (PIIINP) Main materials for "Do It (ELISA Kit) Yourself".